These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 38496341)

  • 21. Efficacy, tolerability, and safety of serotonergic psychedelics for the management of mood, anxiety, and substance-use disorders: a systematic review of systematic reviews.
    Dos Santos RG; Bouso JC; Alcázar-Córcoles MÁ; Hallak JEC
    Expert Rev Clin Pharmacol; 2018 Sep; 11(9):889-902. PubMed ID: 30102078
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lysergic Acid Diethylamide, Psilocybin and Dimethyltryptamine in Depression Treatment: A Systematic Review.
    Więckiewicz G; Stokłosa I; Piegza M; Gorczyca P; Pudlo R
    Pharmaceuticals (Basel); 2021 Aug; 14(8):. PubMed ID: 34451890
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.
    Lowe H; Toyang N; Steele B; Grant J; Ali A; Gordon L; Ngwa W
    Molecules; 2022 Apr; 27(8):. PubMed ID: 35458717
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Trends in the Top-Cited Articles on Classic Psychedelics.
    Lawrence DW; Sharma B; Griffiths RR; Carhart-Harris R
    J Psychoactive Drugs; 2021; 53(4):283-298. PubMed ID: 33535907
    [TBL] [Abstract][Full Text] [Related]  

  • 25. If the Doors of Perception Were Cleansed, Would Chronic Pain be Relieved? Evaluating the Benefits and Risks of Psychedelics.
    Dworkin RH; Anderson BT; Andrews N; Edwards RR; Grob CS; Ross S; Satterthwaite TD; Strain EC
    J Pain; 2022 Oct; 23(10):1666-1679. PubMed ID: 35643270
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exploring the regulatory framework of psychedelics in the US & Europe.
    Behera HK; Joga R; Yerram S; Karnati P; Mergu T; Gandhi K; M S; Nathiya D; Singh RP; Srivastava S; Kumar S
    Asian J Psychiatr; 2024 Sep; 102():104242. PubMed ID: 39305768
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human behavioral pharmacology of psychedelics.
    Strickland JC; Johnson MW
    Adv Pharmacol; 2022; 93():105-132. PubMed ID: 35341564
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review.
    Breeksema JJ; Kuin BW; Kamphuis J; van den Brink W; Vermetten E; Schoevers RA
    J Psychopharmacol; 2022 Oct; 36(10):1100-1117. PubMed ID: 36017784
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Psychedelics and mental health: a population study.
    Krebs TS; Johansen PØ
    PLoS One; 2013; 8(8):e63972. PubMed ID: 23976938
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In the new era of psychedelic assisted therapy: A systematic review of study methodology in randomized controlled trials.
    Soliman PS; Curley DE; Capone C; Eaton E; Haass-Koffler CL
    Psychopharmacology (Berl); 2024 Jun; 241(6):1101-1110. PubMed ID: 38683460
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Psychedelics and Hallucinogens in Psychiatry: Finding New Pharmacological Targets.
    Sousa TR; Rema J; Machado S; Novais F
    Curr Top Med Chem; 2022; 22(15):1250-1260. PubMed ID: 34852736
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Psychedelics: From Cave Art to 21st-Century Medicine for Addiction.
    Vamvakopoulou IA; Nutt DJ
    Eur Addict Res; 2024; 30(5):302-320. PubMed ID: 39321788
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Psychedelics and Psychedelic-Assisted Psychotherapy.
    Reiff CM; Richman EE; Nemeroff CB; Carpenter LL; Widge AS; Rodriguez CI; Kalin NH; McDonald WM;
    Am J Psychiatry; 2020 May; 177(5):391-410. PubMed ID: 32098487
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The risk of chronic psychedelic and MDMA microdosing for valvular heart disease.
    Tagen M; Mantuani D; van Heerden L; Holstein A; Klumpers LE; Knowles R
    J Psychopharmacol; 2023 Sep; 37(9):876-890. PubMed ID: 37572027
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The impact of psychedelics on patients with alcohol use disorder: a systematic review with meta-analysis.
    Sicignano D; Hernandez AV; Schiff B; Elmahy N; White CM
    Curr Med Res Opin; 2024 Feb; 40(2):293-302. PubMed ID: 38111216
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Spatiotemporal Mapping of Online Interest in Cannabis and Popular Psychedelics before and during the COVID-19 Pandemic in Poland.
    Al-Imam A; Motyka MA; Witulska Z; Younus M; Michalak M
    Int J Environ Res Public Health; 2022 May; 19(11):. PubMed ID: 35682204
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Contribution of serotonin 5-HT
    Ibi D
    Nihon Yakurigaku Zasshi; 2023 May; 158(3):229-232. PubMed ID: 36990794
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology.
    Mastinu A; Anyanwu M; Carone M; Abate G; Bonini SA; Peron G; Tirelli E; Pucci M; Ribaudo G; Oselladore E; Premoli M; Gianoncelli A; Uberti DL; Memo M
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674849
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Among psychedelic-experienced users, only past use of psilocybin reliably predicts nature relatedness.
    Forstmann M; Kettner HS; Sagioglou C; Irvine A; Gandy S; Carhart-Harris RL; Luke D
    J Psychopharmacol; 2023 Jan; 37(1):93-106. PubMed ID: 36601974
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiepileptic drugs for chronic non-cancer pain in children and adolescents.
    Cooper TE; Wiffen PJ; Heathcote LC; Clinch J; Howard R; Krane E; Lord SM; Sethna N; Schechter N; Wood C
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD012536. PubMed ID: 28779491
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.